U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Eravacycline – Injection Products
  1. Development Resources

Eravacycline – Injection Products

FDA-Identified Interpretive Criteria

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceaea

≤0.5

-

-

≥15

-

-

Staphylococcus aureus

≤0.06

-

-

-

-

-

Enterococcus faecalis and
Enterococcus faecium

≤0.06

-

-

-

-

-

Streptococcus anginosus groupb

≤0.06

-

-

-

-

-

Anaerobesc

≤0.5

-

-

-

-

-

S=Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 20 mcg eravacycline

a Clinical efficacy was shown for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumonia.
b Clinical efficacy was shown for S. anginosus, S. constellatus, S. intermedius.
c Clinical efficacy was shown for Clostridium perfringens, Parabacteroides distasonis, Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus.

Back to Top